NCT02622555View on ClinicalTrials.gov

Cardiovascular Morbidity During Treatment of Overactive Bladder With B3 Agonists

CompletedOBSERVATIONAL

Enrollment

221

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions

Overactive Bladder

Interventions

DRUG

Mirabegron

Patients with overactive bladder eligible for drug treatment who fulfill the EMA prescription guidelines receive mirabegron 50 mg extended release once daily according to clinical routine

Trial Locations (1)

11449

Daniel Altman, Stockholm

All Listed Sponsors

lead

Karolinska Institutet

OTHER

NCT02622555 - Cardiovascular Morbidity During Treatment of Overactive Bladder With B3 Agonists | Biotech Hunter | Biotech Hunter